Zimmer Biomet HoldingsFRA:ZIM +1.29%76 EBITDA Margin % is 30.68% as of Mar. 2026, which is 28% above its 10-year median of 23.92. GuruFocus rates FRA:ZIM with a GF Score™ of 76/100 and a GF Value™ of €106.93 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 87.62% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zimmer Biomet Holdings EBITDA Margin % Related Terms
Zimmer Biomet Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zimmer Biomet Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ZIM vs PEN, GMED, STE: EBITDA Margin % Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (FRA:ZIM) has a EBITDA Margin % of 30.68% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zimmer Biomet Holdings and its competitors. This is 28% above median its historical median of 23.92. Over the past decade, Zimmer Biomet Holdings' EBITDA Margin % has ranged from 13.35 to 30.03. According to the industry distribution chart, Zimmer Biomet Holdings ranks #101 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 12.4%.
Is Zimmer Biomet Holdings' EBITDA Margin % too high?
Zimmer Biomet Holdings' current EBITDA Margin % of 30.68% is 28% above median its 10-year median of 23.92. Over the past 10 years, this metric has ranged from a low of 13.35 to a high of 30.03. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Zimmer Biomet Holdings' value of 30.68% is 310.4% above this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #101 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zimmer Biomet Holdings has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' EBITDA Margin % compare to PEN and GMED?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #101 out of 816 companies for EBITDA Margin %. This places Zimmer Biomet Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Zimmer Biomet Holdings' value of 30.68% is 310.4% above this benchmark. Historically, Zimmer Biomet Holdings' own EBITDA Margin % has ranged from 13.35 to 30.03 over the past decade. While the company's 10-year median is 23.92 vs. the industry median of 7.48, Zimmer Biomet Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current EBITDA Margin % of 30.68% is 310.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current EBITDA Margin % is 30.68%, which is 28% above median its own 10-year median of 23.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (FRA:ZIM) is currently considered Significantly Undervalued. The stock's GF Value™ is €106.93, compared to a current price of €76.80 — trading 28.2% below its estimated fair value. The current EBITDA Margin % is 30.68%, which is 28% above median its 10-year median of 23.92 and 310.4% above the Medical Devices & Instruments industry median of 7.48. Zimmer Biomet Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zimmer Biomet Holdings (FRA:ZIM), the current EBITDA Margin % is 30.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (FRA:ZIM) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of €76.80 is trading 28.2% below its estimated GF Value™ of €106.93.
GuruFocus considers Zimmer Biomet Holdings to be Significantly Undervalued.
Key valuation signals for FRA:ZIM:
EBITDA Margin %: 30.68% (28% above median its 10-year median of 23.92)
GF Value™: €106.93 vs. price of €76.80 (28.2% below fair value)
Industry Position: 310.4% above the Medical Devices & Instruments median (#101 of 816)
No single metric tells the full story. See the FRA:ZIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
76GF Score
Get the complete analysis for FRA:ZIM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZIM has been successfully added to your 
